bluebird bio, Inc. (49)
Browse by Contract Category
Contracts
-
Underwriting Agreement, dated as of January 18, 2023, by and among bluebird bio, Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC
(Filed With SEC on January 19, 2023)
-
Employment Agreement, dated October 17, 2022, by and between bluebird bio, Inc. and Christopher Krawtschuk
(Filed With SEC on November 7, 2022)
-
Sublease, dated October 31, 2022, by and between Finch Therapeutics, Inc. and bluebird bio, Inc
(Filed With SEC on November 7, 2022)
-
Amendment No
(Filed With SEC on November 7, 2022)
-
Amendment No. 4 to Clinical and Commercial Supply Agreement Viral Vector Product by and between bluebird bio (Switzerland) GmbH and SAFC Carlsbad, Inc
(Filed With SEC on August 4, 2022)
-
Intellectual Property License Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc
(Filed With SEC on November 4, 2021)
-
Asset Purchase Agreement, dated as of January 5, 2023, by and between bluebird bio, Inc. and Bristol-Myers Squibb Company
(Filed With SEC on January 6, 2023)
-
Asset Purchase Agreement, dated as of November 29, 2022, by and between bluebird bio, Inc. and argenx BV
(Filed With SEC on November 30, 2022)
-
Consulting Agreement, dated May 26, 2022, by and between bluebird bio, Inc. and Danforth Advisors, LLC, as amended
(Filed With SEC on November 7, 2022)
-
Consulting Agreement, dated as of September 12, 2022, by and between bluebird bio, Inc. and Jason F. Cole
(Filed With SEC on November 7, 2022)
-
Separation Agreement, dated as of September 12, 2022, by and between bluebird bio, Inc. and Jason F. Cole
(Filed With SEC on November 7, 2022)
-
Amendment to the Transition Services Agreement, by and between 2seventy bio, Inc. and the Registrant
(Filed With SEC on August 4, 2022)
-
Equity Distribution Agreement, dated as of June 22, 2022, by and between bluebird bio, Inc. and Goldman Sachs & Co. LLC
(Filed With SEC on June 22, 2022)
-
Sub-sublease Agreement, by and between the Registrant and Meta Platforms, Inc
(Filed With SEC on March 4, 2022)
-
Offer Letter, dated October 1, 2019, by and between the Registrant and Jessica Whitten
(Filed With SEC on March 4, 2022)
-
Employment Agreement, dated June 14, 2021, by and between the Registrant and Anne-Virginie Eggimann
(Filed With SEC on March 4, 2022)
-
Employment Agreement, dated April 20, 2021, by and between the Registrant and Thomas Klima
(Filed With SEC on March 4, 2022)
-
Employment Agreement, dated June 1, 2021, by and between the Registrant and Gina Consylman
(Filed With SEC on March 4, 2022)
-
Employment Agreement, dated January 7, 2021, by and between the Registrant and Andrew Obenshain
(Filed With SEC on March 4, 2022)
-
Registration Rights Agreement, dated September 7, 2021, by and among the Registrant and the persons listed on the attached Schedule A thereto
(Filed With SEC on November 5, 2021)
-
Securities Purchase Agreement, dated September 7, 2021, by and among the Registrant and the institutional investors named therein
(Filed With SEC on November 5, 2021)
-
Office Lease Agreement, dated November 2, 2021
(Filed With SEC on November 5, 2021)
-
Transition Services Agreement, dated as of November 3, 2021, by and between 2seventy bio, Inc. and bluebird bio, Inc
(Filed With SEC on November 4, 2021)
-
Transition Services Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc
(Filed With SEC on November 4, 2021)
-
Employee Matters Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc
(Filed With SEC on November 4, 2021)
-
Tax Matters Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc
(Filed With SEC on November 4, 2021)
-
Separation Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc
(Filed With SEC on November 4, 2021)
-
Registration Rights Agreement, dated September 7, 2021, by and between the Company and the persons listed on the attached Schedule A thereto
(Filed With SEC on September 8, 2021)
-
Securities Purchase Agreement, dated September 7, 2021, by and among the Company and the institutional investors named therein
(Filed With SEC on September 8, 2021)
-
Form of Pre-Funded Warrant
(Filed With SEC on September 8, 2021)
-
Exclusive Patent License Agreement by and between the Registrant and the National Institutes of Health, dated August 31, 2015
(Filed With SEC on August 9, 2021)
-
License Agreement by and between the Registrant and Biogen Idec MA Inc., dated August 13, 2014
(Filed With SEC on August 9, 2021)
-
Amended and Restated License Agreement by and between the Registrant and Celgene Corporation, dated February 16, 2016
(Filed With SEC on August 9, 2021)
-
Description of the Registrant's Securities
(Filed With SEC on February 23, 2021)
-
Amendment No. 3 to Clinical and Commercial Supply Agreement Viral Vector Product by and between bluebird bio (Switzerland) GmbH and SAFC Carlsbad, Inc
(Filed With SEC on February 23, 2021)
-
Second Amended and Restated License Agreement by and between the Registrant and Celgene Corporation and Celgene European Investment Company LLC, dated May 8, 2020
(Filed With SEC on August 5, 2020)
-
First Amendment to Amended and Restated Co-Development, Co-Promote and Profit Share Agreement by and between the Registrant and Celgene Corporation and Celgene European Investment...
(Filed With SEC on August 5, 2020)
-
Underwriting Agreement, dated as of May 18, 2020, among bluebird bio, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the...
(Filed With SEC on May 19, 2020)
-
Amendment Agreement No. 3 to the Toll Manufacturing and Service Agreement by and between bluebird bio (Switzerland) GmbH and Apceth Biopharma GmbH
(Filed With SEC on March 12, 2020)
-
Description of the Registrant's Securities
(Filed With SEC on February 18, 2020)
-
Amendment No. 2 to Clinical and Commercial Supply Agreement Viral Vector Product by and between bluebird bio (Switzerland) GmbH and SAFC Carlsbad, Inc
(Filed With SEC on January 21, 2020)
-
Amendment to Sublease, dated April 19, 2019, by and between the Registrant and Aventis Inc
(Filed With SEC on August 1, 2019)
-
Sublease, dated April 16, 2019, by and between the Registrant and Aventis Inc
(Filed With SEC on August 1, 2019)
-
Clinical and Commercial Supply Agreement Viral Vector Product, dated November 27, 2017, by and between the Registrant and SAFC Carlsbad, Inc., as amended
(Filed With SEC on August 1, 2019)
-
Toll Manufacturing and Service Agreement, dated November 18, 2016 by and between the Registrant and APCETH Biopharma GmbH, as amended
(Filed With SEC on August 1, 2019)
-
Clinical and Commercial Supply Agreement Viral Vector Product, dated November 27, 2017, by and between the Registrant and SAFC Carlsbad, Inc
(Filed With SEC on February 21, 2019)
-
Toll Manufacturing and Service Agreement, dated November 18, 2016, by and between the Registrant and APCETH Biopharma GmbH
(Filed With SEC on February 21, 2019)
-
License Agreement, dated December 23, 2015, by and between the Registrant and SIRION Biotech GmbH
(Filed With SEC on February 21, 2019)
-
Employment Agreement, dated December 18, 2018, by and between Bluebird and William (Chip) Baird
(Filed With SEC on February 11, 2019)